107 related articles for article (PubMed ID: 12964175)
1. The efficacy of nefazodone augmentation for treatment-resistant depression with anxiety symptoms or anxiety disorder.
Taylor FB; Prather MR
Depress Anxiety; 2003; 18(2):83-8. PubMed ID: 12964175
[TBL] [Abstract][Full Text] [Related]
2. The effect of nefazodone on comorbid anxiety symptoms associated with depression: experience in family practice and psychiatric outpatient settings.
Zajecka JM
J Clin Psychiatry; 1996; 57 Suppl 2():10-4. PubMed ID: 8626357
[TBL] [Abstract][Full Text] [Related]
3. Mixed anxiety and depression in older adults: clinical characteristics and management.
Cassidy EL; Lauderdale S; Sheikh JI
J Geriatr Psychiatry Neurol; 2005 Jun; 18(2):83-8. PubMed ID: 15911936
[TBL] [Abstract][Full Text] [Related]
4. Nefazodone therapy in patients with treatment-resistant or treatment-intolerant depression and high psychiatric comorbidity.
Sajatovic M; DiGiovanni S; Fuller M; Belton J; DeVega E; Marqua S; Liebling D
Clin Ther; 1999 Apr; 21(4):733-40. PubMed ID: 10363738
[TBL] [Abstract][Full Text] [Related]
5. A prospective study of escitalopram in the treatment of major depressive episodes in the presence or absence of anxiety.
Olié JP; Tonnoir B; Ménard F; Galinowski A
Depress Anxiety; 2007; 24(5):318-24. PubMed ID: 17041922
[TBL] [Abstract][Full Text] [Related]
6. [Difficulties in the diagnosis and treatment of major depressive disorder with comorbid anxiety symptoms].
Akkaya C
Turk Psikiyatri Derg; 2006; 17(2):139-46. PubMed ID: 16755414
[TBL] [Abstract][Full Text] [Related]
7. [Residual symptoms after a treated major depressive disorder: in practice ambulatory observatory carried out of city].
Mouchabac S; Ferreri M; Cabanac F; Bitton M
Encephale; 2003; 29(5):438-44. PubMed ID: 14615693
[TBL] [Abstract][Full Text] [Related]
8. Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
Detke MJ; Wiltse CG; Mallinckrodt CH; McNamara RK; Demitrack MA; Bitter I
Eur Neuropsychopharmacol; 2004 Dec; 14(6):457-70. PubMed ID: 15589385
[TBL] [Abstract][Full Text] [Related]
9. Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome.
Howland RH; Rush AJ; Wisniewski SR; Trivedi MH; Warden D; Fava M; Davis LL; Balasubramani GK; McGrath PJ; Berman SR
Drug Alcohol Depend; 2009 Jan; 99(1-3):248-60. PubMed ID: 18986774
[TBL] [Abstract][Full Text] [Related]
10. Affective and anxiety comorbidity in post-traumatic stress disorder treatment trials of sertraline.
Brady KT; Clary CM
Compr Psychiatry; 2003; 44(5):360-9. PubMed ID: 14505296
[TBL] [Abstract][Full Text] [Related]
11. Case study: nefazodone for juvenile mood disorders.
Wilens TE; Spencer TJ; Biederman J; Schleifer D
J Am Acad Child Adolesc Psychiatry; 1997 Apr; 36(4):481-5. PubMed ID: 9100422
[TBL] [Abstract][Full Text] [Related]
12. Escitalopram in the treatment of anxiety symptoms associated with depression.
Bandelow B; Andersen HF; Dolberg OT
Depress Anxiety; 2007; 24(1):53-61. PubMed ID: 16937393
[TBL] [Abstract][Full Text] [Related]
13. Does early improvement triggered by antidepressants predict response/remission? Analysis of data from a naturalistic study on a large sample of inpatients with major depression.
Henkel V; Seemüller F; Obermeier M; Adli M; Bauer M; Mundt C; Brieger P; Laux G; Bender W; Heuser I; Zeiler J; Gaebel W; Mayr A; Möller HJ; Riedel M
J Affect Disord; 2009 Jun; 115(3):439-49. PubMed ID: 19027961
[TBL] [Abstract][Full Text] [Related]
14. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
[TBL] [Abstract][Full Text] [Related]
15. Early improvements in anxiety, depression, and anger/hostility symptoms and response to antidepressant treatment.
Farabaugh A; Sonawalla S; Johnson DP; Witte J; Papakostas GI; Goodness T; Clain A; Baer L; Mischoulon D; Fava M; Harley R
Ann Clin Psychiatry; 2010 Aug; 22(3):166-71. PubMed ID: 20680189
[TBL] [Abstract][Full Text] [Related]
16. Placebo response and antidepressant response.
Alexopoulos GS; Kanellopoulos D; Murphy C; Gunning-Dixon F; Katz R; Heo M
Am J Geriatr Psychiatry; 2007 Feb; 15(2):149-58. PubMed ID: 17272735
[TBL] [Abstract][Full Text] [Related]
17. Psychic and somatic anxiety symptoms as predictors of response to fluoxetine in major depressive disorder.
Papakostas GI; McGrath P; Stewart J; Charles D; Chen Y; Mischoulon D; Dording C; Fava M
Psychiatry Res; 2008 Oct; 161(1):116-20. PubMed ID: 18755514
[TBL] [Abstract][Full Text] [Related]
18. Symptoms of anxiety in depression: assessment of item performance of the Hamilton Anxiety Rating Scale in patients with depression.
Vaccarino AL; Evans KR; Sills TL; Kalali AH
Depress Anxiety; 2008; 25(12):1006-13. PubMed ID: 18800370
[TBL] [Abstract][Full Text] [Related]
19. Pramipexole in treatment-resistant depression: an extended follow-up.
Cassano P; Lattanzi L; Soldani F; Navari S; Battistini G; Gemignani A; Cassano GB
Depress Anxiety; 2004; 20(3):131-8. PubMed ID: 15549689
[TBL] [Abstract][Full Text] [Related]
20. Residual anxiety symptoms in depressed primary care patients.
McIntyre RS; Konarski JZ; Soczynska JK; Kennedy SH
J Psychiatr Pract; 2007 Mar; 13(2):125-8. PubMed ID: 17414691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
